Pharmacokinetics and Dosing Recommendations of Tenofovir Disoproxil Fumarate in Hepatic or Renal Impairment

被引：0
|
作者：
Brian P. Kearney
Kitty Yale
Jaymin Shah
Lijie Zhong
John F. Flaherty
机构：
[1] Gilead Sciences Inc.,
来源：
Clinical Pharmacokinetics | 2006年 / 45卷
关键词：
Fumarate; Tenofovir; Hepatic Impairment; Tenofovir Disoproxil Fumarate; Severe Renal Impairment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Tenofovir disoproxil fumarate is the prodrug of the acyclic nucleotide reverse transcriptase inhibitor tenofovir that is indicated for use in the treatment of HIV. Tenofovir is eliminated as unchanged drug in the urine, with a significant component of active tubular secretion. The aim of this study was to evaluate the pharmacokinetics of tenofovir in subjects with renal or hepatic impairment, both of which are common in HIV-infected individuals.
引用
收藏
页码：1115 / 1124
页数：9
相关论文
共 50 条
  • [1] Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment
    Kearney, Brian P.
    Yale, Kitty
    Shah, Jaymin
    Zhong, Lijie
    Flaherty, John F.
    CLINICAL PHARMACOKINETICS, 2006, 45 (11) : 1115 - 1124
  • [2] Renal safety of tenofovir disoproxil fumarate
    Sax, Paul E.
    Gallant, Joel E.
    Klotman, Paul E.
    AIDS READER, 2007, 17 (02): : 90 - +
  • [3] Tenofovir disoproxil fumarate - Clinical pharmacology and pharmacokinetics
    Kearney, BP
    Flaherty, JF
    Shah, J
    CLINICAL PHARMACOKINETICS, 2004, 43 (09) : 595 - 612
  • [4] Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings
    Moss, John A.
    Baum, Marc M.
    Malone, Amanda M.
    Kennedy, Sean
    Kopin, Etana
    Cali Nguyen
    Gilman, Josh
    Butkyavichene, Irina
    Willis, Robyn A.
    Vincent, Kathleen L.
    Motamedi, Massoud
    Smith, Thomas J.
    AIDS, 2012, 26 (06) : 707 - 710
  • [5] Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
    Lee, Sangmi
    Kim, Eunwoo
    Moon, Seol Ju
    Jung, Jina
    Lee, SeungHwan
    Yu, Kyung-Sang
    TRANSLATIONAL AND CLINICAL PHARMACOLOGY, 2021, 29 (01) : 45 - 52
  • [6] Tenofovir disoproxil fumarate
    Reactions Weekly, 2012, 1432 (1) : 44 - 44
  • [7] Tenofovir Disoproxil Fumarate
    Therese M. Chapman
    Jane K. McGavin
    Stuart Noble
    Drugs, 2003, 63 : 1597 - 1608
  • [8] Tenofovir disoproxil fumarate
    Grim, SA
    Romanelli, F
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (06) : 849 - 859
  • [9] Tenofovir disoproxil fumarate
    Nestor, RJ
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (7-8) : 1148 - 1148
  • [10] Tenofovir disoproxil fumarate (TDF) pharmacokinetics (PK) with daily dosing in the first week of life (HPTN 057)
    Nielsen-Saines, K.
    Mirochnick, M.
    Kumwenda, N.
    Joao, E. C.
    Kreitchmann, R.
    Pinto, J.
    Santos, B.
    Parsons, T.
    Richardson, P.
    Taha, T.
    Mofenson, L.
    Sato, P.
    Kearney, B.
    Fowler, M. G.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 64 - 64
12345